Otezla carries a list price of $4,722 for a 30-day supply, which works out to roughly $56,600 per year. That sticker shock is driven by a combination of patent protection, a massive corporate acquisition that needs to be recouped, and limited competition in its drug class. The good news: prices are set to drop significantly in the next few years.
What You’re Actually Paying For
Otezla (apremilast) is an oral medication approved for four conditions: psoriatic arthritis in adults, moderate to severe plaque psoriasis in adults and children six and older, and oral ulcers from Behçet’s disease. It works by blocking a specific enzyme involved in inflammation. Unlike most other advanced treatments for these conditions, Otezla is a pill rather than an injection, which makes it more convenient but also gives it a unique market position with few direct competitors.
That lack of competition is a big part of the price. Developing drugs in this class has proven difficult. Many similar compounds failed in clinical trials because they caused severe nausea and vomiting, a problem rooted in how closely related the enzyme subtypes are. Designing a molecule selective enough to treat inflammation without triggering those side effects required years of specialized work. The high failure rate across the class means fewer companies successfully brought alternatives to market.
The $13.4 Billion Acquisition
In 2019, Amgen purchased the worldwide rights to Otezla from Celgene for $13.4 billion in cash (about $11.2 billion after tax benefits). The sale happened because federal regulators required Celgene to divest Otezla before completing its merger with Bristol-Myers Squibb, since the combined company would have held too much market power in psoriasis treatments.
That price tag matters because Amgen needs to earn back its investment. When a company pays billions for a single drug, it has strong financial incentive to keep the price high for as long as patent protection allows. Otezla is one of Amgen’s top-selling products, and the acquisition cost effectively sets a floor on how aggressively the company will price it.
Patent Protection Blocks Generic Competition
At least one generic version of apremilast has already been approved by the FDA. A company called Alkem received approval and was granted 180 days of shared generic exclusivity. However, approval doesn’t mean the generic can actually be sold yet. Otezla is protected by multiple patents and periods of market exclusivity that prevent generic manufacturers from launching their products.
The key date is January 20, 2027. That’s when Otezla’s remaining market exclusivity expires and generic companies can begin selling their versions. Beyond that, Amgen holds patents extending as far out as November 2034, though those could potentially be challenged. The practical effect is that until at least early 2027, Amgen faces no price competition from generics in the U.S.
How Otezla Compares to Biologics
One of the arguments sometimes made in Otezla’s favor is that it costs less than injectable biologics. That comparison is more nuanced than it appears. Injectable treatments for psoriasis and psoriatic arthritis typically run between $17,000 and $23,000 per year at list price, with some as high as $32,000 to $39,000 annually. Otezla’s list price of over $56,000 per year now exceeds many of those older biologics, though actual out-of-pocket costs vary widely depending on insurance, rebates, and manufacturer discounts.
The comparison also depends on what you’re measuring. Otezla tends to be less effective than the most potent biologics for severe psoriasis, but it doesn’t require injections or the same level of immune suppression monitoring. For patients with mild to moderate disease, or those who prefer an oral option, it fills a specific niche. That niche positioning, combined with no generic alternatives, gives Amgen pricing leverage.
Medicare Negotiation Will Cut the Price in 2027
Otezla was selected for Medicare’s new drug price negotiation program, and the results are significant. Starting in 2027, Medicare will pay a negotiated price of $1,650 for a 30-day supply, down from the current list price of $4,722. That’s roughly a 65% reduction for Medicare beneficiaries.
This change only applies to Medicare Part D. If you have commercial insurance or are uninsured, the negotiated price won’t directly affect what you pay, though the arrival of generics around the same time should create broader price competition. The convergence of generic entry and Medicare negotiation in 2027 represents a turning point for Otezla affordability.
Patient Assistance Programs
Until prices come down, Amgen runs a copay assistance program called SupportPlus. The program has no income requirement. It covers eligible out-of-pocket costs including copays, deductibles, and coinsurance, up to a maximum annual benefit that Amgen sets on a case-by-case basis. The actual amount you’d receive depends on your specific insurance plan, so the benefit varies from patient to patient.
If you’re currently taking Otezla or considering it, calling 1-833-442-6436 connects you with a support representative who can estimate what your particular coverage would look like under the program. For patients with high-deductible plans or significant coinsurance, this can make the difference between affording the medication and not. Keep in mind that copay cards generally don’t work with Medicare or Medicaid, so those patients will need to wait for the 2027 price changes or explore separate assistance options through Amgen’s broader patient access programs.